DrugPatentWatch Database Preview
EXTINA Drug Profile
When do Extina patents expire, and what generic alternatives are available?
This drug has thirteen patent family members in ten countries.
The generic ingredient in EXTINA is ketoconazole. There are fifteen drug master file entries for this compound. Twenty-eight suppliers are listed for this compound. Additional details are available on the ketoconazole profile page.
Summary for EXTINA
| International Patents: | 13 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 61 |
| Clinical Trials: | 2 |
| Patent Applications: | 9,925 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | see details |
| DailyMed Link: | EXTINA at DailyMed |
Pharmacology for EXTINA
| Ingredient-type | Azoles |
| Drug Class | Azole Antifungal |
| Mechanism of Action | Cytochrome P450 3A4 Inhibitors Cytochrome P450 3A5 Inhibitors P-Glycoprotein Inhibitors |
Medical Subject Heading (MeSH) Categories for EXTINA
Synonyms for EXTINA
| (+-)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine |
| (+)-Ketoconazole |
| (+/-)-cis-1-Acetyl-4-(4-[(2-[2,4-dichlorophenyl]-2-[1H-imidazol-1-ylmethyl]-1,3-dioxolan-4-yl)-methoxy]phenyl)piperazine |
| (+/-)-cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine |
| (2R,4S)-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine |
| (2R,4S)-ketoconazole |
| 1-(4-(4-(((2R,4S)-2-((1H-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)ethan-1-one |
| 1-(4-(4-(((2R,4S)-2-((1H-IMIDAZOL-1-YL)METHYL)-2-(2,4-DICHLOROPHENYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZIN-1-YL)ETHANONE |
| 1-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one |
| 1-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]ethanone |
| 1-acetyl-4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine |
| 142128-59-4 |
| 24F2-1,25(OH)D3 |
| 277K421 |
| 65277-42-1 |
| AB0090681 |
| AB02344 |
| AC-15957 |
| AC1L9UG3 |
| AKOS007930650 |
| API0003081 |
| BDBM60666 |
| BDBM8610 |
| BIDD:GT0696 |
| BIM-0050645.0001 |
| BPBio1_000635 |
| BRD-K29113274-001-03-6 |
| BRN 4303081 |
| BSPBio_000577 |
| C26H28Cl2N4O4 |
| CAS-65277-42-1 |
| CCG-100815 |
| CHEBI:48336 |
| CHEMBL75 |
| CIS-1-ACETYL-4-(4-((2-(2,4-DICHLOROPHENYL)-2-(1H-IMIDAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)PIPERAZINE |
| cis-1-Acetyl-4-[4-[[2-(2,4- |
| cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl] methoxy]phenyl]piperazine |
| cis-1-Acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazine |
| CPD000058460 |
| CS-1846 |
| dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-piperazine |
| DRG-0073 |
| DSSTox_CID_9879 |
| DSSTox_GSID_29879 |
| DSSTox_RID_78829 |
| DTXSID7029879 |
| EI-107 |
| EINECS 265-667-4 |
| EU-0100666 |
| Fungarest |
| Fungoral |
| HMS1569M19 |
| HMS2051A19 |
| HMS2089N05 |
| HMS2096M19 |
| HMS2234H17 |
| HMS3262E13 |
| HSDB 7447 |
| HY-B0105A |
| J10202 |
| K 1003 |
| K0045 |
| KCZ |
| Ketocanazole |
| Ketoconazol |
| ketoconazole |
| Ketoconazole (k) |
| Ketoconazole [USAN:INN:BAN:JAN] |
| Ketoconazole 2.0 mg/ml in Methanol |
| Ketoconazole, >=98% (HPLC) |
| Ketoconazole, Antibiotic for Culture Media Use Only |
| Ketoconazole, British Pharmacopoeia (BP) Reference Standard |
| Ketoconazole, European Pharmacopoeia (EP) Reference Standard |
| Ketoconazole, pharmaceutical secondary standard; traceable to USP and PhEur |
| Ketoconazole, United States Pharmacopeia (USP) Reference Standard |
| Ketoconazolum |
| Ketoderm |
| Ketoisdin |
| KS-1205 |
| KTN |
| KTZ |
| Kuric |
| KZ |
| Lopac0_000666 |
| LP00666 |
| LS-110149 |
| MCULE-2726394491 |
| MFCD00058579 |
| MLS000069784 |
| MLS000758224 |
| MLS001146934 |
| MLS001423987 |
| MLS002207053 |
| MLS002222255 |
| MolPort-003-848-307 |
| MRF-0000100 |
| NC00065 |
| NCGC00016907-01 |
| NCGC00025000-01 |
| NCGC00025000-02 |
| NCGC00025000-03 |
| NCGC00025000-04 |
| NCGC00025000-05 |
| NCGC00025000-06 |
| NCGC00025000-07 |
| NCGC00025000-08 |
| NCGC00025000-09 |
| NCGC00025000-10 |
| NCGC00253967-01 |
| NCGC00261351-01 |
| Nizoral |
| NSC 317629 |
| Opera_ID_397 |
| Piperazine, (+)-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]- |
| Piperazine, (+/-)-1-acetyl-4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-, rel- |
| Piperazine, 1-acetyl-4-(4-((2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-, cis- |
| Prestwick_744 |
| Prestwick0_000389 |
| Prestwick1_000389 |
| Prestwick2_000389 |
| Prestwick3_000389 |
| Q-201267 |
| R 41,400 |
| R-41400 |
| R41,400 |
| R41400 |
| rac-trans-Ketoconazole |
| s1353 |
| SAM001246983 |
| SCHEMBL8407 |
| SMR000058460 |
| SPBio_002498 |
| SR-01000075626 |
| SR-01000075626-1 |
| SR-01000597381 |
| SR-01000597381-6 |
| ST2407064 |
| Tocris-1103 |
| Tox21_110676 |
| Tox21_300267 |
| Tox21_500666 |
| UNII-R9400W927I component XMAYWYJOQHXEEK-OZXSUGGESA-N |
| UPCMLD-DP138 |
| UPCMLD-DP138:001 |
| US9150527, Ketoconazole |
| W-2941 |
| Xolegel |
| ZINC643138 |
US Patents and Regulatory Information for EXTINA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Pharms Inc | EXTINA | ketoconazole | AEROSOL, FOAM;TOPICAL | 021738-001 | Jun 12, 2007 | AT | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Mylan Pharms Inc | EXTINA | ketoconazole | AEROSOL, FOAM;TOPICAL | 021738-001 | Jun 12, 2007 | AT | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Paragraph IV (Patent) Challenges for EXTINA
| Drugname | Dosage | Strength | RLD | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Foam | 2% | ➤ Subscribe | 2009-07-30 |
Non-Orange Book US Patents for EXTINA
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,586,066 | Topical antifungal composition | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
